170 likes | 245 Views
This analysis explores Accelrys, a division of Pharmacopeia Inc., offering software for pharmaceutical, biotechnology, and chemical research. Discover their products, services, key executives, and strategic alliances.
E N D
An Analysis of Accelrys Imran Mohiuddin
Pharmacopeia Inc. • Offers products and services enabling drug and chemical discovery. • Accelrys is the software development division of Pharmacopeia Inc.
Basic Information • Accelrys was developed in the 1980s, apparently an international effort. • Claims to have ~600 employees worldwide. • 50% of staff are Ph.D. scientists specializing in disciplines across chemistry, biology, and materials research. • complemented by employees educated in software and systems engineering and project management.
Basic Information • Main Headquarters in San Diego. • Also maintain “Centers of Excellence” in Cambridge, UK and Bangalore, India. • Publicly traded on NASDAQ (ACCL). • Reported a 2003 revenue of $86 million.
Accelrys? • The company specializes in providing software for research and development in pharmaceuticals, biotechnology, and chemicals. • In addition to its biotechnology customer base, Accelrys also serves a wide range of other trades, including the automotive, aerospace, electronics, and energy industries.
Discovery Studio • Chemistry multi-tool to aid in drug development. • “Complete range of life science applications spanning scientific disciplines within a single unified platform. Enables scientists to capture, manage, analyze, and use biological and chemical data and information within an integrated system.”
Materials Studio • Advanced materials simulation and informatics. • “Dramatically enhances your ability to mine, analyze, present, and communicate data and information relating to chemicals and materials.“
Informatics • Bioinformatics - manage, organize, apply biological/genome information. • Cheminformatics - manage, organize, apply chemical information. • Matinformatics - manage, organize, apply information related to materials.
Modeling, Simulation, and Analysis • Molecular Graphics - Use 3D modeling to understand chemical structure • Statistical. Correlations - Analyze data to build statistical models that explain and predict properties. • Atomistic Simulation - Predict the behavior of chemical and biological systems .
Modeling, Simulation, and Analysis • Quantum Mechanics - Accurate prediction of chemical properties and reactivity. • Mesoscale Modeling - Predict key processes in complex fluids and soft materials. • Structure Characterization - Characterize molecular structure, often based on data from analytical instruments.
Customers • Academic Institutions • Government Labs • Pharmaceutical corporations (DuPont) • Biotechnology companies (Genaissance) • Chemical companies (Dow) • Other industries, including automotive, aerospace, electronics, and energy.
Strategic Business Aliances • IBM • HP • Sun Microsystems • Oracle • Intel • More
Executives • CEO - Mark J. Emkjer • CEO Mark J. Emkjer, was previously President and Chief Operating Officer of Sunquest Information Systems, Inc., a $150 million information technology business that develops laboratory, radiology and pharmacy systems. Prior to joining Sunquest, he was President and Chief Executive Officer of Pace Health Management Systems, Inc., a provider of clinical decision support software.
Executives • CFO - John J. Hanlon • John J. Hanlon was President and CFO of a publicly held e-payment service provider. He also spent 10 years as CFO of MDL Information Systems, Inc., a provider of integrated scientific information management systems, databases and services, and an additional 10 years in public accounting at Coopers and Lybrand.
Executives • HOT - Dr. Scott Kahn • Received his Ph.D. in Theoretical Organic Chemistry from the University of California, Irvine, after which he did post-doctoral work at Cambridge University, UK. Dr. Kahn is an experienced software developer and created analysis tools for medicinal chemistry research and modeling.
Will it Work? • Net Income • 2000 - $1175 • 2001 - $14,320 • 2002 - $11,627 • 2003 - $3,497